搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
pharmaphorum
25 分钟
PBM reform dropped in Congress' funding package
The stripping of the legislation from the short-term funding package was described as a "missed opportunity" by the National ...
pharmaphorum
2 小时
FDA clears Ionis drug as first therapy for rare disease FCS
Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome ...
pharmaphorum
4 小时
Lilly grabs first-ever FDA nod for a sleep apnoea drug
Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...
pharmaphorum
4 小时
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
pharmaphorum
6 天
Galderma adds new indication for blockbuster hope Nemluvio
Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...
pharmaphorum
4 天
UnitedHealth killing suspect gets first-degree murder charge
First-degree murder charges are applied when there is suspicion of premeditated, intentional killing, while second-degree ...
pharmaphorum
3 天
Novo completes $16.5bn takeover of Catalent
Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...
pharmaphorum
3 天
Neuralink rival Precision raises $102m, and other financings
While Neuralink has been grabbing headlines due to its association with controversial billionaire Musk, other companies - ...
pharmaphorum
4 天
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
pharmaphorum
3 天
Vertex weakens after neuropathic pain trial reads out
Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...
pharmaphorum
6 天
Tech & Trials: Recruiting is hard, AI can make it easier
Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...
pharmaphorum
3 天
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈